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Increased oxidative stress and mitochondrial damage are among the mechanisms whereby mutant SOD1
(mutSOD1) associated with familial forms of amyotrophic lateral sclerosis (ALS) induces motoneuronal
death. The 66 kDa isoform of the growth factor adapter Shc (p66Shc) is known to be central in the control
of mitochondria-dependent oxidative balance. Here we report that expression of mutSOD1s induces the ac-
tivation of p66Shc in neuronal cells and that the overexpression of inactive p66Shc mutants protects cells
from mutSOD1-induced mitochondrial damage. Most importantly, deletion of p66Shc ameliorates mitochon-
drial function, delays onset, improves motor performance and prolongs survival in transgenic mice model-
ling ALS. We also show that p66Shc activation by mutSOD1 causes a strong decrease in the activity of the
small GTPase Rac1 through a redox-sensitive regulation. Our results provide new insight into the potential
mechanisms of mutSOD1-mediated mitochondrial dysfunction.
INTRODUCTION
Damage to mitochondria is emerging as a central feature that
contributes to the degeneration of motor neurons in amyo-
trophic lateral sclerosis (ALS). Recent evidence indicates
that mitochondria are one of the primary location of damage
inside motor neurons (1), but also astrocytes and muscle
cells, which both have been involved in the disease, show def-
icits in mitochondrial metabolism (2–4). Dysfunction of mito-
chondria is observed early in patients (and in experimental
models for ALS) and causes the death of neurons, which
underlies onset of paralysis and death of patients. A large
body of studies in cells and mice overexpressing mutSOD1s,
which model many characteristics of the disease, have
addressed different aspects of mitochondrial dysfunction oc-
curring in ALS, ranging from altered morphology (swelling
and fragmentation) (5–8) to impaired activity of respiratory
chain complexes (9,10), weakened calcium buffering capacity
(11) and mitochondria-dependent execution of apoptosis (12–
14). Moreover, recent investigations have drawn attention to
the presence of a generalized energetic imbalance both in
patients and in mice, suggesting that ubiquitous defects in
mitochondrial physiology might contribute to the disease
process (15,16).
Compelling evidence has accumulated that uncontrolled
association of mutSOD1 with mitochondria may be directly
responsible for mitochondrial impairment (6,17,18), either
by decreasing protein import selectively in spinal cord
mitochondria (19) or by binding and inactivating specific
mitochondrial targets such as the voltage-dependent anion
channel 1 (20), the anti-apoptotic protein Bcl-2 (21) or the
mitochondrial form of lysyl-tRNA synthetase (22). However,
there is also indication that mitochondrial localization might
not be necessary for mutant SOD1 (mutSOD1) to damage
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mitochondria (23), suggesting that cytosolic signals, yet to be
identified, mediate the transfer of the inherent toxic properties
of mutSOD1 to mitochondria.
A novel, mitochondria-related signalling mechanism in-
volving the 66 kDa isoform of the growth factor adapter Shc
(p66Shc), which is operative in conditions of oxidative
stress, has been recently identified. The protein p66Shc is an
alternatively spliced isoform of a growth factor adapter that
is phosphorylated upon oxidative stress (24). In this form, a
fraction of p66Shc localizes to mitochondria, where it binds
to cytochrome c and acts as an oxidoreductase, generating
ROS and leading to organelle dysfunction and cell death
(25). p66Shc2/2 mice exhibit a 30% extended lifespan,
reduced H2O2 levels and an enhanced resistance against oxida-
tive stress (26), indicating that p66Shc acts as a key molecular
sentinel that controls cellular stress responses and mammalian
lifespan.
On the basis of these considerations, we have investigated
the role of p66Shc in mutSOD1-induced cell toxicity, as
well as the functional consequences of p66Shc ablation in
transgenic mice overexpressing G93A-SOD1.
RESULTS
Apoptosis induced by mutSOD1 is accompanied by
phosphorylation of p66Shc at serine 36
p66Shc is phosphorylated on a serine residue in position 36 in
response to cellular stress induced by various stimuli, and this
event is crucial to p66Shc-mediated oxidative stress and apop-
tosis (26,27). As an initial step to investigate the role of
p66Shc in mutSOD1-induced cell stress, human wild-type or
G93A-SOD1, the most studied SOD1 mutation associated
with familial amyotrophic lateral sclerosis (fALS), was transi-
ently overexpressed in SH-SY5Y human neuroblastoma cells
by adenoviral infection. In these conditions, G93A-SOD1
induces the sequential activation of caspase-3, cleavage of
PARP and accumulation of fragmented nuclei, all suggestive
of an ongoing apoptotic process (Fig. 1). Similar results
were obtained when SH-SY5Y cells were infected with the
fALS mutant H80R-SOD1 (Fig. 7 and not shown), indicating
that the pro-apoptotic effect is common to fALS-linked
SOD1s. In contrast, infection with adenoviruses expressing
wtSOD1 or a control GFP protein (not shown) has no
evident effects. To determine whether p66Shc is activated
by mutSOD1 through phosphorylation on Ser36, total lysates
from cells were immunoprecipitated with an anti-Shc antibody
and analysed by western blotting using an antibody that specif-
ically recognizes phosphorylated p66Shc at Ser36. Expression
of G93A mutSOD1, but not of wtSOD1, induces p66Shc phos-
phorylation at Ser36 (Fig. 2A), whereas the expression levels
of all Shc protein isoforms (p46, p52 and p66) are not affected.
Overexpression of dominant-negative, functionally inactive
p66Shc proteins protects cells against mutSOD1-induced
mitochondrial damage and apoptosis
To investigate the functional relevance of the phosphorylation
of p66Shc at Ser36 induced by mutSOD1, SH-SY5Y cells
stably overexpressing a serine 36-to-alanine (and therefore
non-phosphorylatable) mutant of p66Shc (S36A; Fig. 2B)
were infected with adenoviruses coding for wild-type SOD1
or G93A mutSOD1 and analysed after 72 h for apoptotic
markers. As shown in Figure 2B, the number of apoptotic
cells generated by mutSOD1 is reduced by 90% in cells
expressing the S36A mutant of p66Shc, and a similar decrease
Figure 1. mutSOD1 induces apoptosis in SH-SY5Y cells. (A) SH-SY5Y cells were infected with adenoviruses coding for wild-type SOD1 (wtSOD1) or the
fALS G93A-SOD1 mutant. After 72 h, nuclei of cells were stained with Hoechst 33342, and apoptotic nuclei were quantified as described in Materials and
Methods. (B) Cells were infected as in (A) and analysed after 48 h by indirect immunofluorescence analysis with antibodies against SOD1 (green) or the
active form of caspase-3 (activeC3, red). Cell nuclei are in blue. (C) After 72 h of expression of the indicated SOD1s, nuclear and cytosolic fractions from
cells were isolated. Nuclei were analysed in western blot with antibodies recognizing the cleaved form of PARP1. The nuclear protein Lamin B was analysed
as a standard for equal protein loading. Cytosolic fractions were also controlled for the expression of SOD1. Owing to the high levels of overexpressed exogenous
mutSOD1s, endogenous mouse SOD1 in control cells is not evident in this exposure.
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in caspase-3 activity is observed (Fig. 2C). These data thus in-
dicate that the phosphorylation of p66Shc plays a role in
mutSOD1-induced cell death.
The pro-oxidant, pro-apoptotic activities of p66Shc depend
upon two defined regions of the protein: two glutamic residues
at position 132 and 133, the site where the redox activity of
p66Shc has been mapped (25), and a cysteine at position 59,
a regulatory disulphide/thiol site mediating a reversible
dimer–tetramer transition, which has been proposed to
control the protein’s apoptosis-inducing activity (28). When
overexpressed in SH-SY5Y cells, both the E132Q/E133Q
(EEQQ) and the C59S mutant p66Shc proteins are able to
inhibit the pro-apoptotic activity of G93A mutSOD1, as mea-
sured by PARP cleavage, similar to what is observed with the
S36A mutant (Fig. 2D). On the contrary, overexpression of
wild-type p66Shc enhances the mutSOD1-induced apoptosis.
Overall, these observations strongly indicate that p66Shc med-
iates the toxic effects exerted by mutSOD1.
It has been shown that mitochondrial Ca2+ responsiveness,
which is a highly sensitive readout of mitochondrial state (27),
is dramatically compromised after p66Shc activation.
Therefore, using the aequorin technology to monitor mito-
chondrial Ca2+ signalling (29), we analysed the effects of
both wild-type and mutSOD1 proteins on SH-SY5Y cells dis-
playing different background for p66Shc, i.e. in wild-type
SH-SY5Y cells, in SH-SY5Y cells overexpressing the
mutant S36A-p66Shc, in SH-SY5Y cells overexpressing the
mutant EEQQ-p66Shc and in SH-SY5Y cells overexpressing
wild-type p66Shc.
In SH-SY5Y cells, application of carbachol, an extracellular
agonist acting on a Gq-coupled receptor, causes the production
of inositol 1,4,5-trisphosphate and thus the release of Ca2+
from the endoplasmic reticulum and the transient increase of
cytosolic and mitochondrial [Ca2+] (29).
In wild-type SH-SY5Y cells (Fig. 3A), the overexpression
of wild-type SOD1 causes an increased mitochondrial
[Ca2+] ([Ca2+]m) response after agonist stimulation. On the
contrary, the overexpression of two different mutSOD1s
causes a drastic reduction in the Ca2+ spike evoked by
agonist stimulation, as an early consequence of mitochondrial
damage as previously reported after p66Shc activation during
oxidative stress (27).
Figure 2. Functionally inactive mutant p66Shc protects cells from mutSOD1-induced apoptosis. (A) SH-SY5Y cells were infected with adenoviruses coding for
wtSOD1 or the G93A mutSOD1. After the indicated times, cell lysates were subjected to immunoprecipitation with an anti-Shc antibody. Immunoprecipitates
were analysed in western blot with an antibody recognizing p66Shc phosphorylated on serine 36 (p66P). The blot was re-probed with an anti-Shc antibody to
check for equal protein input. (B) Control (ctrl) SH-SY5Y cells, or cells stably overexpressing the S36A non-phosphorytable p66Shc mutant, were infected as in
(A). After 72 h, cells were stained with Hoechst 33342 and apoptotic nuclei quantified. Values significantly different from relative controls are indicated with an
asterisk when P, 0.01 (n ¼ 3). (C) Cells treated as in (A) were assayed for the activity of caspase-3, expressed in arbitrary units. Two different clones of S36A
p66Shc cells were analysed. Values significantly different from relative controls are indicated with an asterisk when P , 0.01 (n ¼ 3). (D) Control SH-SY5Y
cells, or cells stably overexpressing the S36A, C59S or E132Q/E133Q (EEQQ) mutants of p66Shc, were infected with adenoviruses coding for wtSOD1 or the
G93A mutSOD1. After 72 h, nuclear and cytosolic fractions from cells were isolated. Nuclear fractions were analysed in western blot with antibodies
anti-cleaved PARP1 and anti-lamin B, whereas cytosolic fractions were analysed with anti-SOD1 and anti-Shc.
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The presence of p66Shc mutant proteins (Fig. 3C and D)
confers mitochondrial insensitiveness to mutSOD1, since the
mitochondrial Ca2+ response after agonist stimulation is
almost unaffected by the presence of mutSOD1. On the con-
trary, the alteration of mitochondrial responsiveness induced
by mutSOD1 is maintained in SH-SY5Y cells overexpressing
wild-type p66Shc (Fig. 3B).
We have recently shown that mutSOD1 induces alterations
in mitochondrial bioenergetics and morphology of SH-SY5Y
cells (5). To test whether these effects arise as a consequence
of p66Shc activation, ATP production and mitochondrial
morphology were assayed in cells overexpressing wild-type
or mutSOD1 together with p66Shc mutant proteins. To
analyse the mitochondrial capability for energy production,
ATP concentration in SH-SY5Y cells exposed to mutSOD1s
was measured. An [ATP] decrease was evident in cells over-
expressing G93A or H80R mutSOD1 (Fig. 3E); in contrast,
cells co-expressing functionally inactive p66Shc show a
physiological ATP concentration.
As observed by immunofluorescence analysis of SH-SY5Y
cells using antibodies anti-SOD1 and SOD2, a mitochondrial
matrix protein (Fig. 4, left), cells expressing the G93A
mutSOD1 show a significant alteration of the filamentous
mitochondrial network which characterizes most of the
untransfected or wild-type SOD1-transfected cells, with mito-
chondria appearing fragmented and swollen. Similarly, the
filamentous network is essentially lost when cells are chal-
lenged with H2O2. On the contrary, in cells expressing the
p66Shc EEQQ mutant (Fig. 4, right), the overall filamentous
network is maintained either in the presence of mutSOD1 or
after H2O2 treatment. Similar results were obtained with the
S36A mutant p66Shc (not shown).
On the whole, these data clearly indicate that p66Shc is the
effector downstream of mutSOD1 responsible for the altera-
tions of mitochondrial physiology that eventually lead to cell
death.
Ablation of p66Shc significantly ameliorates ALS
phenotype in mice
To learn whether transgenic G93A-SOD1 mice, an accepted
model for ALS linked to mutSOD1, would be rescued by
genetic removal of p66Shc, we crossed these mice with
p66Shc2/2 mice (26) and determined several behavioural
and biochemical parameters.
As shown in Figure 5B, p66Shc is highly expressed in the
spinal cord of control mice, as well as wtSOD1 or
G93A-SOD1 transgenic mice, and only to a lower extent in
the brain and muscle. As expected, ablation of p66Shc does
not affect the levels of expression of transgenic SOD1 in the
spinal cord. As shown in Figure 5A, G93A-SOD1/
p66Shc2/2 mice show significantly delayed onset of the
disease (118.96+ 10.98 versus 98.07+ 8.9 days, P,
0.0001), improved motor performance as measured by
rotarod test and increased survival (141.26+ 14.42 versus
157.50+ 9.11 days, P , 0.0001) with respect to
G93A-SOD1 mice. Such striking effects are paralleled by
improved mitochondrial function specifically in the spinal
cord, where the activity of complex IV is restored (Fig. 5C)
together with the ratio between reduced and oxidized glutathi-
one (GSH/GSSG) in mitochondria, which is an indicator of the
redox state of the cell (Fig. 5D).
p66Shc mediates the toxicity of mutSOD1 through
Rac1 inactivation
To learn more on the molecular mechanisms of
mutSOD1-induced p66Shc toxicity, and to attempt the dissec-
tion of such mechanisms in vitro, we focused on Rac1, a
member of the Rho family of small GTPases, which controls
many intracellular processes, including ROS production and
cytoskeletal dynamics, and whose activity has been linked to
the activity of both SOD1 and p66Shc (30,31).
Figure 3. mutSOD1s cause mitochondrial damage in a p66Shc-dependent
manner. Control SH-SY5Y cells (A), or cells stably overexpressing wild-type
p66Shc (B), the S36A (C) or E132Q/E133Q (EEQQ, D) mutants of p66Shc,
were infected with adenoviruses expressing wtSOD1 and the G93A or
H80R mutSOD1s, together with an adenovirus expressing a mitochondrial tar-
geted aequorin chimera. After 36 h, cells were challenged with 1 mM charba-
col. The light signal was collected and calibrated into [Ca2+] values by an
algorithm based on the Ca2+ response curve of aequorin at physiological con-
ditions of pH, [Mg2+] and ionic strength. Statistical data are presented as
mean+SEM. (E) SH-SY5Y cells, or cells stably overexpressing S36A or
EEQQ mutant p66Shc, were infected with adenoviruses expressing wtSOD1
and the G93A or H80R mutSOD1s. After 48 h, total amount of ATP was
assayed. The ATP concentration was normalized to total cellular protein con-
centration and expressed as percent of the relative, uninfected controls. Values
are reported as mean+SD. Values significantly different from relative con-
trols are indicated with an asterisk when P , 0.05 (n ¼ 3).
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Overexpression of both G93A and H80R mutant proteins
decreases the levels of active, GTP-bound form of Rac1 in
SH-SY5Y cells, compared with control and wtSOD1-
expressing cells, as measured by a GST-PAK1 pull-down
assay (Fig. 6A and B). The effect is specific for Rac1, since
mutSOD1s do not significantly affect the activity of either
RhoA or Cdc42, two small GTPases functionally related to
Rac1 (Fig. 6A and B). Moreover, the overexpression by adeno-
viral infection of a constitutive active (V12) form of Rac1
completely protects SH-SY5Y cells from mutSOD1-induced
apoptosis, whereas the expression of a dominant-negative, in-
active (N17) mutant of Rac1 has no effect (Fig. 7). Significant-
ly, N17 Rac1 is able to induce apoptosis in control cells, and to
re-establish the apoptotic phenotype in cells where apoptosis
induced by mutSOD1s overexpression has been hampered by
co-expression of functional inactive mutants of p66Shc
(Fig. 8A and B), suggesting that Rac1 acts downstream of
p66Shc. More importantly, in cells expressing the dominant-
negative mutant p66Shc-S36A, Rac1 is active even in the
presence of mutSOD1s (Fig. 9A); on the contrary, when a wild-
type p66Shc protein is overexpressed in cells, Rac1 activity
is dramatically compromised by mutSOD1s (Fig. 9B).
Altogether, these data thus clearly indicate that p66Shc activa-
tion is an obligatory step for mutSOD1 to inhibit Rac1, which in
turn leads to cell death.
p66Shc downregulates Rac1 activity through a
redox-dependent mechanism
It has been recently shown that the activity of Rac1 is physio-
logically controlled by the redox environment of the cell,
according to a mechanism where SOD1 itself exerts a
primary role (30). To test whether a redox-dependent mechan-
ism could account for the inhibition of Rac1 activity following
p66Shc activation, control SH-SY5Y cells or cells overexpres-
sing a functional inactive mutant of p66Shc (S36A) were
treated with H2O2 and the amount of GTP-Rac1 was assayed
accordingly. Indeed, increasing concentration of H2O2
induces a proportional decrease in Rac1 activity, and this
effect is associated with a strong decrease in cell viability
(Fig. 10A and B). The expression of an S36A p66Shc
mutant almost completely prevents H2O2-induced cell death,
and in this condition the decrease in the activity of Rac1 is pre-
cluded (Fig. 10B and C). These results prompted us to inves-
tigate whether the activity of Rac1 could be affected by factors
controlling the intracellular pool of GSH, which is the major
determinant of the cellular redox state (32). As shown in
Figure 10D, treatment of cells overexpressing mutSOD1
with the cell-permeable ethyl ester form of reduced GSH
(GEE), which results in an increase in intracellular GSH,
significantly restores Rac1 activity, whereas depletion of
Figure 4. p66Shc inhibition prevents mitochondrial fragmentation induced by mutSOD1. SH-SY5Y control cells or p66Shc/EEQQ overexpressing cells were left
untreated, or infected with adenoviruses coding for the indicated SOD1s. After 48 h, cells were subjected to immunofluorescence analysis with anti-SOD1
(green) and anti-SOD2 (red) antibodies. As a control for mitochondrial fragmentation, SH-SY5Y cells were treated with 500 mM H2O2 for 30 min and processed
for mitochondrial staining as above. Higher magnifications of areas highlighted in insets are shown.
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cytoplasmic GSH with L-buthionine-(S,R)-sulfoximine (BSO)
has a striking inhibitory effect on the activity of Rac1.
DISCUSSION
In the present study, we show that inhibition of mitochondrial
redox signalling by p66Shc is able to rescue viability in cell
models and to improve survival in the mouse model for
fALS linked to mutSOD1.
Indeed, it has been shown, both in models and patients, that
the pathological phenotypes of ALS well correlate with altera-
tions in all the processes related to or controlling mitochon-
drial function, i.e. morphology and bioenergetics,
transportation and clearance, apoptosis and calcium buffering
(33), thus sustaining a direct role of mitochondrial dysfunction
in motor neuron degeneration in ALS pathogenesis.
However, evidence linking mitochondrial abnormalities to
ALS is yet incomplete. Most of all, it is not entirely clear
whether, and to what extent, mitochondrial preservation
could be beneficial to the disease. To answer these questions,
we decided to focus on p66Shc as a central regulator of mito-
chondrial ROS metabolism and the mitochondrial apoptosis
pathway (24). p66Shc responds to a variety of stimuli by in-
creasing ROS levels in the mitochondrial intermembrane
space through an ROS-producing activity (25). The
physiological role of this process is currently unknown, al-
though it is clear that it might participate in the control of
intracellular redox-based signal transduction pathways (34).
These mechanisms are indeed relevant for the process of apop-
tosis, since p66Shc-mediated formation of ROS triggers the
initiation of the mitochondrial apoptosis pathway, and more
generally for the regulation of lifespan (26) and energy metab-
olism (35,36), which are intimately connected. Moreover,
p66Shc has a function in various pathological conditions
where oxidative stress plays a role, such as arteriosclerosis
(37) and endothelial dysfunctions (38).
Although it has been initially suggested that other, non-
mitochondrial activities of p66Shc might be needed to exert
its pro-apoptotic function (25), activation of the p66Shc
pathway has emerged as a clear readout of mitochondrial
damage in cells (39), and data presented in this work clearly
point to the intrinsic, mitochondrial redox activity of p66Shc
in mediating the toxicity exerted by mutSOD1. Different
lines of evidence support this conclusion: (i) the accumulation
in cells expressing mutSOD1 of p66Shc species phosphory-
lated on serine 36, a critical regulatory site for the mitochon-
drial pro-apoptotic activity of p66Shc (27), and the rescuing
effect on cell viability of the non-phosphorylatable S36A
p66Shc mutant; (ii) the inhibitory effect over the toxic
action of mutSOD1s of the EEQQ and C59S p66Shcs, two
Figure 5. Downregulation of p66Shc ameliorates ALS phenotype in mice. (A) Transgenic mice overexpressing G93A-SOD1 were crossed with p66Shc2/2
mice and characterized for onset (grip test, top panel), motor performance (rotarod test, middle panel) and survival (bottom panel). Equal numbers of males
and females were analysed for each genoptype. No sex-dependence was observed and therefore data were pooled. Number of animals tested (n) and the
median onset and survival probabilities (arrowheads) are shown. Values significantly different from relative controls are indicated with an asterisk when
P, 0.01. (B) Western blot analysis of SOD1 and p66Shc in the brain (B), muscle (M) and spinal cord (Sc) from G93A-SOD1 and G93A-SOD1/
p66Shc2/2 mice. As a control, p66Shc expression was analysed in non-transgenic mice and in mice overexpressing wild-type SOD1. (C) Complex IV activity
were determined from mitochondria extracted from spinal cord of G93A-SOD1 and G93A-SOD1/p66Shc2/2 mice. Values are reported as mean+SD. Values
significantly different from relative controls are indicated with an asterisk when P, 0.05 (n ¼ 3). (D) HPLC determination of GSH/GSSG ratio in mitochondria
extracted from spinal cord of G93A-SOD1 and G93A-SOD1/p66Shc2/2 mice. Values are reported as mean+SD. Values significantly different from relative
controls are indicated with an asterisk when P , 0.05 (n ¼ 3).
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mutants that are specifically endowed with mitochondrial
redox activity (25,28); (iii) the recovery of mitochondrial
function (as measured by rescued mitochondrial Ca2+ buffer-
ing capacity, ATP production and mitochondrial morphology)
and of cell viability obtained by the expression of functionally
inactive mutant p66Shcs. On the whole, these data clearly
support the notion that the p66Shc mitochondrial pathway is
a key effector responsible for the alterations of mitochondrial
physiology evoked by mutSOD1. This conclusion is further
supported by our data in vivo, in transgenic mice overexpres-
sing mutant G93A-SOD1 but lacking p66Shc, where onset,
motor performance and survival are significantly improved, to-
gether with mitochondrial functionality, and is in agreement
with recent findings showing that blocking the mitochondrial
apoptotic pathway preserves motor neuron viability and func-
tion in a mouse model of ALS (40). Of note, although a strik-
ing effect of p66Shc removal is obtained on the disease onset
in these mice, the outcome on the overall disease progression
is relatively minor. This would indicate a central role of mito-
chondrial dysfunction in mediating disease initiation by
mutSOD1, and of p66Shc as an important player participating
in this process.
To clarify the molecular mechanisms by which p66Shc
activation is responsible for neuronal cell damage induced
by overexpression of mutSOD1s, we analysed the functional
relationship between activation of p66Shc by mutSOD1 and
Rac1, a prominent member of Rho family of small
GTPases. Rac1 is an intracellular transducer known to regu-
late multiple signalling pathways that control the organization
of cytoskeleton, gene expression and cell proliferation (41).
Rac1 and its relatives are also essential regulators of
NADPH-dependent membrane oxidase (NOX) that produces
superoxide anions, in both phagocytic and non-phagocytic
cells (42), according to a mechanism where SOD1 itself
seems to play a pivotal role. Indeed, Harraz et al. (30)
have recently shown that when superoxide anions produced
by microglial NOX exceed a physiological threshold, they
are converted to hydrogen peroxide by SOD1, which normal-
ly binds to Rac1 itself and stimulates its activity. H2O2 then
leads to the oxidative inactivation of Rac1, to the detachment
of SOD1 from Rac1 and eventually to silencing of Rac1-
dependent activity of NOX.
Similar to Harraz et al. (30), we also observed that Rac1 ac-
tivity is strictly controlled, among other mechanisms, by redox
conditions. However, we found that active Rac1 and cell via-
bility are directly linked in neuronal cells, and that cell death
induced by mutSOD1s is achieved through a
p66Shc-dependent inhibition of Rac1, whereas it has been
clearly shown that the pro-inflammatory activity of
mutSOD1-expressing microglial cells relies on an uncon-
trolled, constitutive activation of Rac1 (30). Further, p66Shc
was proposed to promote Rac1 activation (31), thereby trig-
gering ROS production by NOX, whereas in our cell model,
p66Shc activation is clearly responsible for Rac1 inhibition.
The reasons for these apparent discrepancies can be partially
explained by differences in the cellular milieu (neurons
versus glia) and by the fact that the activity of Rho family
GTPases is strictly dependent on their subcellular distribution
and compartmentalization, which again can be profoundly dif-
ferent between neuronal and glial cells.
Nonetheless, different lines of evidence support a role of
Rac1 inhibition in the process of neurodegeneration in ALS.
Mutations in alsin, which are responsible for a recessive
form of juvenile-onset ALS, are predicted to affect the
guanine nucleotide exchange factor (GEF) activity of this
Figure 6. MutSOD1 proteins decrease Rac1-GTP levels in SH-SY5Y cells.
(A) SH-SY5Y cells were infected with adenoviruses expressing wild-type or
the G93A and H80R mutSOD1s. After 72 h, GTP-bound Rac1 and Cdc42
were pulled-down by a GST-PAK protein, whereas GTP-RhoA was pulled-
down with a GST-Rothekin protein, both conjugated to GSH–sepharose.
The GTP-bound (active) as well as the total (input) amounts of GTPases
were detected in western blot using the indicated antibodies. Lysates were
also analysed for SOD1 expression. (B) Quantification of active Rho
GTPases in cells treated as in (A). The amounts of active GTPases were nor-
malized to inputs and are expressed as mean+SD of arbitrary densitometric
units relative to control, non-infected cells. Values significantly different from
relative controls are indicated with an asterisk when P , 0.01 (n ¼ 4).
Figure 7. A constitutively active (V12) form of Rac1 completely protects
SH-SY5Y cells from mutSOD1-induced apoptosis. SH-SY5Y cells were
infected with adenoviruses expressing wild-type or the G93A (left panel)
and H80R (right panel) mutSOD1s, in the absence or in the presence of ade-
noviruses coding for constitutive active (V12) or inactive (N17) mutants of
Rac1. After 72 h, nuclear fractions from cells were isolated and analysed in
western blot with antibodies anti-cleaved PARP1 and anti-lamin
B. Cytosolic fractions were analysed with anti-SOD1, anti-Rac1 and
anti-b-actin antibodies.
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protein (43,44). Alsin knockdown inhibits axon growth and
induces cell death in cultured motoneurons. Notably, these
cellular phenotypes are mimicked by expression of a
dominant-negative Rac1 mutant and are completely blocked
by expression of a constitutively active Rac1 mutant (45).
Overexpression of alsin protects NSC34 cells from
mutSOD1-induced apoptosis, and this neuroprotective activity
is completely inhibited by knocking down the endogenous
Rac1 expression with siRNA for Rac1 (46). On the whole,
these observations clearly point to disruption of Rac1
GTPase function as a causative event of motor neuron degen-
eration. This conclusion is further supported by recent results
obtained in neuronal cells depleted of the 43 kDa TAR DNA-
binding protein (TDP-43), a major component of the ubiquiti-
nated inclusions characteristic of ALS and frontotemporal
lobar degeneration with ubiquitin-positive inclusions, whose
mutations have been causally linked to familial ALS. The
knockdown of TDP-43 in differentiated Neuro-2a cells inhi-
bits neurite outgrowth and induces cell death through the in-
activation of Rho family members RhoA and Rac1, and
Cdc42 GTPases. These effects are associated with the inhib-
ition of protein geranylgeranylation, a key post-translational
modification for Rho family activity and intracellular localiza-
tion (47). Our results point to a direct role of ROS in Rac1 in-
activation, as suggested by the observation that the decrease of
Rac1 activity by both hydrogen peroxide or mutSOD1 is pre-
vented by inhibition of p66Shc-dependent mitochondrial
redox signalling or by increased intracellular concentration
of GSH. This is in line with recent findings indicating that
GTPases may also be directly controlled by redox agents
(48), a mechanism of regulation that may be particularly rele-
vant in pathological conditions, such as ALS, where ROS are
generated and the cellular redox balance altered.
In conclusion, our data emphasize that mitochondrial redox
signalling, p66Shc and Rac1 are linked by an intimate connec-
tion in neurons in vitro and in vivo, in adult mice. That such
connections are altered in a genetic context mimicking part
of ALS patients strongly supports the concept that molecules
involved in this signalling play an important role in this
disease.
Figure 8. A constitutively inactive (N12) form of Rac1 re-establishes the
apoptotic phenotype in cells overexpressing functional inactive mutants of
p66Shc. Control SH-SY5Y cells, or SH-SY5Y cells expressing the S36A,
C59S (A) or EEQQ (B) p66Shc mutants, were infected with adenoviruses
coding for wild-type or the G93A and H80R mutSOD1s, in the absence or
in the presence of adenoviruses expressing constitutive active (V12) or in-
active (N17) mutants of Rac1. After 72 h, nuclear and cytosolic fractions
from cells were isolated. Nuclear fractions were analysed in western blot
with antibodies anti-cleaved PARP1 and anti-lamin B, cytosolic fractions
with anti-Shc and anti-SOD1.
Figure 9. Inhibition of p66Shc prevents the downregulation of Rac1 activity
induced by mutSOD1s. Control SH-SY5Y or SH-SY5Y cells expressing the
S36A (A) or the wild-type (B) p66Shc proteins were infected with adeno-
viruses expressing wild-type SOD1 or the G93A and H80R mutSOD1s.
After 72 h, GTP-bound Rac1 was analysed with a GST-PAK pull-down
assay. The GTP-bound (active) as well as the total (input) amounts of Rac1
GTPase were detected in western blot using an anti-Rac1 antibody. Lysates
were also analysed for p66Shc and SOD1 expression. The numbers represent
fold activity above normalized activity in control uninfected cells (referred to
as 1.0); densitometric scanning of the films was used to determine relative
levels of Rac1 activation versus protein amounts. The data are representative
of n ¼ 3 independent experiments.
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MATERIALS AND METHODS
Plasmid construction
Human cDNA coding for p66Shc (accession number U73377)
was cloned by reverse transcription-PCR from human
SH-SY5Y neuroblastoma cells cDNA, using the forward
primer 5′ AAA AAG CTT ATG GAT CTC CTG CCC CCC
3′ and the reverse primer 5′ TTT CTC GAG TCA CAG
TTT CCG CTC CAC 3′. The resulting PCR fragment was
inserted into HindIII/XhoI restriction sites of pcDNA3 (Invi-
trogen). For the mutagenesis of p66Shc, PCR site-directed mu-
tagenesis was performed using pcDNA3/p66Shc as template,
followed by digestion with Dpn1. All the plasmid construc-
tions were verified by automated sequencing.
Cell culture, plasmid transfection and adenoviral infection
Human neuroblastoma cells, SH-SY5Y, were purchased from
the European Collection of Cell Culture and grown in DMEM
(Invitrogen) supplemented with 10% fetal calf serum (FCS,
Euroclone), at 378C in an atmosphere of 5% CO2 in air. For
stable expression of wild-type or mutant p66Shc, cells were
co-transfected with plasmids coding for different p66Shc pro-
teins in the presence of 1:20 of a plasmid coding for hygromy-
cin resistance, using Lipofectamine Plus reagent (Invitrogen).
After selection with 400 mg/ml hygromycin (Invitrogen),
about 20 clones for each construct were isolated independently
and analysed in western blot with anti-Shc antibodies. At least
three clones for each plasmid were chosen for equivalent ex-
pression of p66Shc proteins and used for further analysis.
All the clones analysed gave consistent results and data from
one clone are shown.
Construction of recombinant adenoviruses expressing wild-
type SOD1, as well as G93A and H80R mutSOD1, was carried
out by inserting cDNAs coding for the different SOD1s into
the pShuttle2 and BD Adeno-X viral DNA (BD Bioscience).
Transient transfections of HEK293 cells were performed
using Lipofectamine 2000 (Invitrogen). Viral titre was deter-
mined by dilution assay using HEK293 cells according to
the manufacturer’s instructions. Adenoviruses were propa-
gated in HEK293 cells as described in Latella et al. (49). In-
fection of SH-SY5Y cells was carried out for 1 h in
OPTIMEM; after removal of the virus, cells were grown for
the indicated period of times before being subjected to
further experimental manipulations. To optimize the protocol
for SH-SY5Y infection, cells were infected with Ad-GFP
and Ad-SOD1s, and expression was measured by immunoblot-
ting and immunofluorescence with the antibody anti-SOD1.
Efficiency of infection was 90% at a multiplicity of infec-
tion (m.o.i.) of 1000 after infection for 48 h. V12 and N17
Rac1 adenoviruses were described in Cozzolino et al. (50)
and used at an m.o.i. of 50.
Nuclei isolation and cleaved PARP1 analysis
On 60 mm Petri dishes, 1.5 × 106 SH-SY5Y cells were plated.
After the indicated treatments, cells were rinsed in ice-cold
PBS and lysed in 150 ml of low-salt buffer (10 mM Hepes,
pH 7.4, 42 mM KCl, 5 mM MgCl2, 0.5 % CHAPS, 1 mM
DTT, 1 mM PMSF, 1 mg/ml leupeptin). After centrifugation
at 2000g, nuclei were resuspended in 50 ml of high-salt
buffer (50 mM Tris–HCl, pH 7.5, 400 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.5% Nonidet-P40, 10% glycerol,
2 mM DTT, 1 mM PMSF, protease inhibitor cocktail. After
30 min on ice, lysates were centrifuged at 20 000g, superna-
tants were collected and analysed as nuclear fractions in
western blot with antibodies anti-cleaved PARP1 (Cell
Signal) and anti-Lamin B (Santa Cruz Biotechnology).
Assessment of apoptosis and cell viability
Quantification of apoptotic cells was obtained by direct visual
counting after nuclear staining of 4% paraformaldehyde-fixed
cells with the fluorescent probe Hoechst 33342 (1 mg/ml)
(Sigma-Aldrich). One hundred cells were examined for each
field at a magnification of 200× and eight randomly chosen
fields for each experimental condition were counted. Only
the cells containing clearly picnotic or fragmented nuclei
were considered apoptotic. Caspase 3 activity was measured
with a TruePoint Caspase 3 assay kit (PerkinElmer), accord-
ingly to the manufacturer’s instructions.
Figure 10. Redox regulation of Rac1 activity by mutSOD1. (A) SH-SY5Y
cells were treated with the indicated amounts of H2O2. After 24 h, active
Rac1 was measured by a GST-PAK pull-down assay. (B) The viability of
control SH-SY5Y cells or SH-SY5Y cells expressing the S36A mutant
p66Shc and treated with 50 mM H2O2 was calculated after 24 h through an
MTS assay. (C) The activity of Rac1 was measured in cells treated as in
(B). (D) SH-SY5Y cells were infected with adenoviruses expressing
wtSOD1 or the H80R mutSOD1, in the absence or in the presence of 5 mM
GEE. Control cells were also treated with 10 mM BSO. After 72 h, cell
lysates were subjected to GST-PAK pull-down assay for the assessment of
Rac1 activity. The numbers represent fold activity above normalized activity
in control uninfected cells (referred to as 1.0). The data are representative of
n ¼ 3 independent experiments.
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Cell viability was assessed by a colorimetric assay using the
3(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter 96
Aqueous One Solution Assay, Promega), according to the
manufacturer’s instructions. Absorbance at 490 nm was mea-
sured in a multilabel counter (Victor3-V, PerkinElmer Life
Sciences).
Mitochondrial Ca21 measurements
Cells were seeded before transfection onto 13 mm glass cover
slips and allowed to grow to 50% confluence. At this stage, the
cells were infected with the adenovirus expressing a mitochon-
drial targeted aequorin chimera. Thirty-six hours after infec-
tion, the cover slips with the cells were incubated with 5 mM
coelenterazine for 1–2 h in DMEM supplemented with 1%
FCS, and then transferred to the perfusion chamber. All
aequorin measurements were carried out in KRB (Krebs–
Ringer modified buffer: 125 mM NaCl, 5 mM KCl, 1 mM
Na3PO4, 1 mM MgSO4, 5.5 mM glucose, 20 mM HEPES, pH
7.4, 378C) supplemented with 1 mM CaCl2. The agonist,
1 mM carbachol, was then added to the same medium. The
experiments were terminated by lysing the cells with 100 mM
digitonin in a hypotonic Ca2+-rich solution (10 mM CaCl2 in
H2O), thus discharging the remaining aequorin pool. The
light signal was collected and calibrated into [Ca2+] values
by an algorithm based on the Ca2+ response curve of aequorin
at physiological conditions of pH, [Mg2+] and ionic strength,
as previously described (29). Statistical data are presented as
mean+SEM, significance was calculated by Student’s t-test
and correlation analysis was done with the SigmaPlot 5.0 soft-
ware (SPSS, Inc.).
Immunofluorescence analysis
For immunofluorescence analysis, cells cultured on
poly-L-lysine-coated glass cover slip were washed in PBS
and fixed with 4% paraformaldehyde in PBS for 10 min.
Fixed cells were washed in PBS followed by permeabilization
with 0.1% Triton X-100 in PBS for 5 min. Cells were blocked
for 1 h in 2% horse serum in PBS and incubated for 1 h at
378C with primary antibodies: mouse monoclonal anti-active
casp3 (Cell Signaling), rabbit anti-SOD1 (Stressgen), rabbit
anti-SOD2 (Stressgen), mouse monoclonal anti-SOD1 (clone
SD-G6, Sigma-Aldrich). Cells were washed in blocking
buffer and incubated for 1 h with an Alexa Fluor 488 goat anti-
mouse (Invitrogen) and Cy3 goat anti-rabbit (Jackson Immu-
noResearch Laboratories) antibodies. After rinsing in PBS,
cells were stained with 1 mg/ml Hoechst 33342
(Sigma-Aldrich) and examined under a Zeiss LSM 510 con-
focal microscopy. Fluorescence images were processed using
Adobe Photoshop.
Measurement of cellular ATP
Measurement of cellular ATP was performed using the
ATPlite Assay (Perkin Elmer-Cetus, Norwalk, CT, USA). In
brief, cells seeded in 96-well microplates were resuspended
in 50 ml of lysis buffer and mixed for 10 min. Forty microlitres
of substrate solution (Luciferase/Luciferin) was added to each
sample. The luminescence was measured using a lumines-
cence plate reader (Victor3-V, PerkinElmer Life Sciences).
The ATP concentration was normalized to total cellular
protein concentration estimated by Bradford protein assay
(Bio-Rad).
Rho family pull-down assay
The Rac-GTP and Cdc42-GTP pull-down assay was per-
formed as previously described (50). Briefly, cells were
lysed in a buffer containing 50 mM Tris, pH 7.2, 100 mM
NaCl, 5 mM MgCl2, 1 mM DTT, 10% glycerol, 1%
Nonidet-P40, plus protease inhibitors. One-fiftieth of cell
lysates were subjected to immunoblotting. Cell lysates were
mixed with 10 mg of bacterially expressed GST-PAK (rat
PAK amino acids 1–252) bound to GSH–sepharose and incu-
bated at 48C with tumbling for 30 min. Beads were collected
by centrifugation and washed twice in lysis buffer before add-
ition of Laemmli buffer and analysis by western blot with
anti-Rac1 and anti-Cdc42 antibodies. For the RhoA-GTP pull-
down assay, cell lysis and washes were done in 50 mM Tris–
Cl, pH 7.2, 500 mM NaCl, 1% (v/v) Triton X-100, 5 mM
MgCl2, 1 mM DTT and protease inhibitors. Bacterially
expressed GST-Rhotekin (murine amino acids 7–89) bound
to GSH–sepharose was used in place of PAK.
Immunoprecipitation
After rinsing the cultures with ice-cold PBS, cell lysis was per-
formed in RIPA buffer (50 mM Tris–HCl, 0.5% Triton X-100,
0.25% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM
EDTA, 5 mM MgCl2) containing 1 mM PMSF and a protease
inhibitor cocktail (Sigma-Aldrich). A clear supernatant was
obtained by centrifugation of lysates at 17 000g for 10 min.
Protein content was determined using Bradford protein assay
(Bio-Rad). Equal amounts of lysates were incubated at 48C
for 2 h with a rabbit polyclonal anti-Shc antibody (Cell
Signal) and the immunocomplexes were collected by
binding to protein A-Agarose beads (Roche), followed by
three washes with lysis buffer.
Electrophoresis and western blot
Standard SDS–PAGE was performed as described (10).
Western blot was performed onto nitrocellulose membranes
(Amersham), except for RhoA, Rac1 and Cdc-42 that were
blotted onto PVDF membranes (Millipore). After incubation
in Tris-buffered saline (TBS) solution containing 0.1%
Tween 20 and 5% non-fat milk, filters were incubated for
2 h at room temperature with the indicated antibodies diluted
in a 2% non-fat milk, 0.1% Tween 20/TBS solution. Immunor-
eactive SOD1 was detected with a rabbit polyclonal
anti-SOD1 antibody (Stressgen). p66Shc proteins were
detected using a mouse monoclonal anti-Shc antibody which
recognizes all the three isoforms of Shc (p46, p52 and p66).
Phosphorylated p66Shc on serine 36 was detected using a
mouse monoclonal specific antibody (Alexis). A goat antibody
(Santa Cruz Biotechnology) was used to detect the cleaved
form of PARP1. Antibodies anti-RhoA and Cdc42 were
from Santa Cruz Biotechnology. Anti-Rac1 was from
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Millipore. b-Actin was detected using a mouse monoclonal
antibody from Sigma. A goat antibody anti-Lamin B was
from Santa Cruz Biotechnology.
Following extensive washing in 0.1% Tween 20/TBS solu-
tion, filters were incubated with the appropriated peroxidase-
conjugated secondary antibodies, washed in 0.1% Tween 20/
TBS solution and developed using the POD chemilumines-
cence detection system (Roche). Image analysis and quantifi-
cations were performed by Kodak Image Station (KDS
IS440CF 1.1) with 1D Image Analysis software.
Animals
All animal procedures have been performed according to the
European Guidelines for the use of animals in research (86/
609/CEE) and the requirements of Italian laws (D.L. 116/
92). The ethical procedure has been approved by the Animal
Welfare Office, Department of Public Health and Veterinary,
Nutrition and Food Safety, General Management of Animal
Care and Veterinary Drugs of the Italian Ministry of Health.
At the indicated time, mice were anaesthetized with
500 mg/kg chloral hydrate, sacrificed and dissected for the dif-
ferent experiments. All efforts were made to minimize suffer-
ing. All animals have been raised and crossed in the indoor
animal house in a 12 h light/dark cycle in a virus/antigen-free
facility with controlled temperature and humidity and have
been provided with water and food ad libitum.
Wild-type SOD1 mice B6.Cg-Tg(SOD1)2Gur/J and
SOD1G93A mice B6.Cg-Tg(SOD1∗G93A)1Gur/J were pur-
chased from The Jackson Laboratory and were on C57BL/6J
background. p66Shc2/2 mice were also in the C57BL/6J
background.
Mice compared in this study were all littermates and housed
together to minimize environmental factors. Mice were geno-
typed using PCR protocols from The Jackson Laboratory.
Western blot analysis for p66Shc and SOD1 expression was
carried out as described above on total protein extracts from
various tissues obtained through homogenization in RIPA
buffer.
Symptom onset, survival and rotarod analysis
Behavioural analysis was performed according to the standard
operating procedures indicated by Ludolph et al. (51). Briefly,
mice were considered terminally paralysed if they were unable
to right themselves after 10 s of being placed on their side. To
assess symptom onset, mice were subjected to grip test twice a
week, starting at 70 days of age. Rotarod testing was per-
formed using the accelerating rotarod apparatus (Ugo Basile
7650 model). The rod was accelerated at a constant rate of
4 r.p.m. starting from 3 r.p.m. for a maximum of 5 min. The
time (seconds) at which the animal fell from the bar was
recorded. Mice were tested twice a week for three trials,
each starting at 80 days of age, until they were unable to
remain on the rotarod for at least 20 s. The best trial per day
was recorded and used for analysis. Each time point represents
the mean+SE of performance of all mice at each data point
as previously described (52).
Determination of complex IV activity and GSH/GSSG ratio
were carried out on purified mitochondria as previously
described (10).
Statistical analysis
Statistical analysis of rotarod data was performed using
ANOVA. Kaplan–Meier curves were compared using the
log-rank test. Comparisons of protein expression levels,
complex IV activity and values of GSH/GSSG ratio were per-
formed using two-tailed unpaired Student’s t-test. P-values of
,0.05 were considered significant.
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